Previous 10 | Next 10 |
CohBar, Inc. (CWBR) Q3 2022 Results Conference Call November 8, 2022 10:00 AM ET Company Participants Jordyn Tarazi - Director of IR Joseph Sarret - CEO Kent Grindstaff - SVP, Research Jeffrey Biunno - CFO Conference Call Participants Kemp Dollive...
CohBar press release ( NASDAQ: CWBR ): Q3 GAAP EPS of -$0.82. The company had cash, cash equivalents and investments of $18.3 million as of September 30, 2022, compared to $26.2 million as of December 31, 2021. For further details see: CohBar GAAP EPS of -$0.82 ...
MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...
MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...
CohBar ( NASDAQ: CWBR ) shares gained 16% premarket on Thursday after the biotech firm announced a 1-for-30 reverse stock split of its common stock. The move is intended to enable the company to regain compliance with the Nasdaq $1.00 minimum bid price requirement. The...
MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related disease...
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related disease...
CohBar, Inc. (CWBR) Q2 2022 Earnings Conference Call August 15, 2022, 05:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Parti...
CohBar press release ( NASDAQ: CWBR ): Q2 GAAP EPS of -$0.03 beats by $0.01 . The company had cash, cash equivalents and investments of $20.1 million as of June 30 IND for CB5138-3 on track for second half of 2023 For further details see: CohBar GAAP EPS ...
IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitoch...
News, Short Squeeze, Breakout and More Instantly...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...